{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T18:16:52Z","timestamp":1769883412613,"version":"3.49.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T00:00:00Z","timestamp":1666137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T00:00:00Z","timestamp":1666137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Bioinformatics"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Few studies have demonstrated that the relationship between m6A-related genes and the prognosis, tumor microenvironment and drug resistance of LC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The main results were analyzed with bioinformatics methods.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Hence, we found 10 m6A-related genes expressed less in tumor samples in comparison with normal ones. Using consensus clustering, all LC patients were grouped into 2 subgroups according to the overall expression of 10 differential expressed m6A-related genes. In two clusters, the OS and immune characteristics were different. We analyzed the predictive potential of 10 m6A-related genes in the prognosis of LC, and obtained a risk prognosis model on the strength of ZC3H13, CBLL1, ELAVL1 and YTHDF1 as the hub candidate genes through LASSO cox. The expression of 4 hub m6A-related genes was validated by IHC in the HPA database. The infiltration level of dendritic cell, CD4+ T cell and neutrophil that were affected by CNV level of m6A-related genes in LUAD and LUSC patients. Moreover, based on GSCALite database, we found that LUSC patients with hypermethylation tended to have a better overall survival. In terms of drug sensitivity, etoposide correlated negatively with ELAVL1, HNRNPC, RBM15B, YTHDF2 and CBLL1. ZC3H13 had positively association with afatinib, while HNRNPC was positively associated with dasatinib, erlotinib, lapatinib and TGX221. Crizotinib had a negative correlation with ELAVL1, CBLL1, HNRNPC and RBM15B.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In conclusion, m6A-related genes are important participants in LC and the expression levels of ZC3H13, CBLL1, ELAVL1 and YTHDF1 are significant for prediction and treatment of LC. Researches of drug resistance based on m6A-related genes need to pay more attention for producing new therapeutic strategies of LC and CBLL1 may contribute to target treatment for further research.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12859-022-04984-5","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T15:02:43Z","timestamp":1666191763000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Study on the prognosis, immune and drug resistance of m6A-related genes in lung cancer"],"prefix":"10.1186","volume":"23","author":[{"given":"Yang","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhouyao","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingyang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiting","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuji","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,19]]},"reference":[{"issue":"3","key":"4984_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"4984_CR2","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa1916623","volume":"383","author":"N Howlader","year":"2020","unstructured":"Howlader N, et al. The effect of advances in lung-cancer treatment on population mortality. N Engl J Med. 2020;383(7):640\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1916623.","journal-title":"N Engl J Med"},{"issue":"1","key":"4984_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ccm.2019.10.001","volume":"41","author":"BC Bade","year":"2020","unstructured":"Bade BC, Dela Cruz CS. Lung cancer 2020: epidemiology, etiology, and prevention. Clin Chest Med. 2020;41(1):1\u201324. https:\/\/doi.org\/10.1016\/j.ccm.2019.10.001.","journal-title":"Clin Chest Med"},{"issue":"6","key":"4984_CR4","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1016\/j.athoracsur.2020.07.048","volume":"111","author":"PA Cowper","year":"2021","unstructured":"Cowper PA, et al. Initial and longitudinal cost of surgical resection for lung cancer. Ann Thorac Surg. 2021;111(6):1827\u201333. https:\/\/doi.org\/10.1016\/j.athoracsur.2020.07.048.","journal-title":"Ann Thorac Surg"},{"issue":"15","key":"4984_CR5","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1158\/1078-0432.CCR-18-1538","volume":"25","author":"DB Doroshow","year":"2019","unstructured":"Doroshow DB, et al. Immunotherapy in non-small cell lung cancer: facts and hopes. Clin Cancer Res. 2019;25(15):4592\u2013602. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1538.","journal-title":"Clin Cancer Res"},{"key":"4984_CR6","doi-asserted-by":"publisher","first-page":"103194","DOI":"10.1016\/j.critrevonc.2020.103194","volume":"157","author":"EN Imyanitov","year":"2021","unstructured":"Imyanitov EN, Iyevleva AG, Levchenko EV. Molecular testing and targeted therapy for non-small cell lung cancer: current status and perspectives. Crit Rev Oncol Hematol. 2021;157:103194. https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103194.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"4984_CR7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41571-020-00432-6","volume":"18","author":"M Oudkerk","year":"2021","unstructured":"Oudkerk M, et al. Lung cancer LDCT screening and mortality reduction\u2014evidence, pitfalls and future perspectives. Nat Rev Clin Oncol. 2021;18(3):135\u201351. https:\/\/doi.org\/10.1038\/s41571-020-00432-6.","journal-title":"Nat Rev Clin Oncol"},{"issue":"Suppl 2","key":"4984_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/resp.13870","volume":"25","author":"SK Vinod","year":"2020","unstructured":"Vinod SK, Hau E. Radiotherapy treatment for lung cancer: current status and future directions. Respirology (Carlton, VIC). 2020;25(Suppl 2):61\u201371. https:\/\/doi.org\/10.1111\/resp.13870.","journal-title":"Respirology (Carlton, VIC)"},{"issue":"8","key":"4984_CR9","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1001\/jama.2019.11058","volume":"322","author":"KC Arbour","year":"2019","unstructured":"Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review. JAMA. 2019;322(8):764\u201374. https:\/\/doi.org\/10.1001\/jama.2019.11058.","journal-title":"JAMA"},{"issue":"3","key":"4984_CR10","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.jtho.2018.11.023","volume":"14","author":"LM Seijo","year":"2019","unstructured":"Seijo LM, et al. Biomarkers in lung cancer screening: achievements, promises, and challenges. J Thorac Oncol. 2019;14(3):343\u201357. https:\/\/doi.org\/10.1016\/j.jtho.2018.11.023.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"4984_CR11","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s12943-019-1106-z","volume":"18","author":"T Lan","year":"2019","unstructured":"Lan T, et al. KIAA1429 contributes to liver cancer progression through N6-methyladenosine-dependent post-transcriptional modification of GATA3. Mol Cancer. 2019;18(1):186. https:\/\/doi.org\/10.1186\/s12943-019-1106-z.","journal-title":"Mol Cancer"},{"issue":"8","key":"4984_CR12","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1080\/15548627.2019.1586246","volume":"15","author":"H Song","year":"2019","unstructured":"Song H, et al. METTL3 and ALKBH5 oppositely regulate m(6)A modification of TFEB mRNA, which dictates the fate of hypoxia\/reoxygenation-treated cardiomyocytes. Autophagy. 2019;15(8):1419\u201337. https:\/\/doi.org\/10.1080\/15548627.2019.1586246.","journal-title":"Autophagy"},{"issue":"3","key":"4984_CR13","doi-asserted-by":"publisher","first-page":"e105977","DOI":"10.15252\/embj.2020105977","volume":"40","author":"PC He","year":"2021","unstructured":"He PC, He C. m(6) A RNA methylation: from mechanisms to therapeutic potential. EMBO J. 2021;40(3):e105977. https:\/\/doi.org\/10.15252\/embj.2020105977.","journal-title":"EMBO J"},{"key":"4984_CR14","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.omtn.2019.11.022","volume":"19","author":"W Zhao","year":"2020","unstructured":"Zhao W, et al. Epigenetic regulation of m(6)A modifications in human cancer. Mol Ther Nucleic acids. 2020;19:405\u201312. https:\/\/doi.org\/10.1016\/j.omtn.2019.11.022.","journal-title":"Mol Ther Nucleic acids"},{"issue":"21","key":"4984_CR15","doi-asserted-by":"publisher","first-page":"12706","DOI":"10.1111\/jcmm.15848","volume":"24","author":"X Huang","year":"2020","unstructured":"Huang X, et al. m6A RNA methylation regulators could contribute to the occurrence of chronic obstructive pulmonary disease. J Cell Mol Med. 2020;24(21):12706\u201315. https:\/\/doi.org\/10.1111\/jcmm.15848.","journal-title":"J Cell Mol Med"},{"issue":"2","key":"4984_CR16","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41576-020-00295-8","volume":"22","author":"D Wiener","year":"2021","unstructured":"Wiener D, Schwartz S. The epitranscriptome beyond m(6)A. Nat Rev Genet. 2021;22(2):119\u201331. https:\/\/doi.org\/10.1038\/s41576-020-00295-8.","journal-title":"Nat Rev Genet"},{"issue":"1","key":"4984_CR17","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12943-019-1109-9","volume":"18","author":"L He","year":"2019","unstructured":"He L, et al. Functions of N6-methyladenosine and its role in cancer. Mol Cancer. 2019;18(1):176. https:\/\/doi.org\/10.1186\/s12943-019-1109-9.","journal-title":"Mol Cancer"},{"issue":"1","key":"4984_CR18","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41392-020-00450-x","volume":"6","author":"X Jiang","year":"2021","unstructured":"Jiang X, et al. The role of m6A modification in the biological functions and diseases. Signal Transduct Target Ther. 2021;6(1):74. https:\/\/doi.org\/10.1038\/s41392-020-00450-x.","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"4984_CR19","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1038\/s41589-019-0349-8","volume":"15","author":"J Wei","year":"2019","unstructured":"Wei J, He C. Site-specific m(6)A editing. Nat Chem Biol. 2019;15(9):848\u20139. https:\/\/doi.org\/10.1038\/s41589-019-0349-8.","journal-title":"Nat Chem Biol"},{"issue":"11","key":"4984_CR20","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda A, et al. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747\u201356. https:\/\/doi.org\/10.1101\/gr.239244.118.","journal-title":"Genome Res"},{"issue":"21","key":"4984_CR21","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.1093\/bioinformatics\/bty411","volume":"34","author":"CJ Liu","year":"2018","unstructured":"Liu CJ, et al. GSCALite: a web server for gene set cancer analysis. Bioinformatics (Oxford, England). 2018;34(21):3771\u20132. https:\/\/doi.org\/10.1093\/bioinformatics\/bty411.","journal-title":"Bioinformatics (Oxford, England)"},{"issue":"5","key":"4984_CR22","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1681\/ASN.2020101418","volume":"32","author":"T Vaulet","year":"2021","unstructured":"Vaulet T, et al. Data-driven derivation and validation of novel phenotypes for acute kidney transplant rejection using semi-supervised clustering. J Am Soc Nephrol. 2021;32(5):1084\u201396. https:\/\/doi.org\/10.1681\/ASN.2020101418.","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"4984_CR23","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/bioinformatics\/btq170","volume":"26","author":"MD Wilkerson","year":"2010","unstructured":"Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics (Oxford, England). 2010;26(12):1572\u20133. https:\/\/doi.org\/10.1093\/bioinformatics\/btq170.","journal-title":"Bioinformatics (Oxford, England)"},{"issue":"30","key":"4984_CR24","doi-asserted-by":"publisher","first-page":"5512","DOI":"10.1002\/sim.3148","volume":"26","author":"W Sauerbrei","year":"2007","unstructured":"Sauerbrei W, Royston P, Binder H. Selection of important variables and determination of functional form for continuous predictors in multivariable model building. Stat Med. 2007;26(30):5512\u201328. https:\/\/doi.org\/10.1002\/sim.3148.","journal-title":"Stat Med"},{"issue":"6","key":"4984_CR25","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1093\/neuonc\/now285","volume":"19","author":"X Hu","year":"2017","unstructured":"Hu X, et al. Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma. Neuro Oncol. 2017;19(6):786\u201395. https:\/\/doi.org\/10.1093\/neuonc\/now285.","journal-title":"Neuro Oncol"},{"issue":"11","key":"4984_CR26","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.18632\/aging.101625","volume":"10","author":"Z Zhou","year":"2018","unstructured":"Zhou Z, et al. Identification of an energy metabolism-related signature associated with clinical prognosis in diffuse glioma. Aging. 2018;10(11):3185\u2013209. https:\/\/doi.org\/10.18632\/aging.101625.","journal-title":"Aging"},{"issue":"18","key":"4984_CR27","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1158\/0008-5472.CAN-18-3962","volume":"79","author":"DC Hinshaw","year":"2019","unstructured":"Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Can Res. 2019;79(18):4557\u201366. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-3962.","journal-title":"Can Res"},{"issue":"20","key":"4984_CR28","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.1093\/bioinformatics\/btz210","volume":"35","author":"Ru Beibei","year":"2019","unstructured":"Beibei Ru, et al. TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics. 2019;35(20):4200\u20132. https:\/\/doi.org\/10.1093\/bioinformatics\/btz210.","journal-title":"Bioinformatics"},{"issue":"21","key":"4984_CR29","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","volume":"77","author":"T Li","year":"2017","unstructured":"Li T, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Can Res. 2017;77(21):e108\u201310. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-0307.","journal-title":"Can Res"},{"issue":"w1","key":"4984_CR30","doi-asserted-by":"publisher","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","volume":"48","author":"T Li","year":"2020","unstructured":"Li T, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(w1):W509\u201314. https:\/\/doi.org\/10.1093\/nar\/gkaa407.","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"4984_CR31","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/path.2440","volume":"216","author":"F Pont\u00e9n","year":"2008","unstructured":"Pont\u00e9n F, Jirstr\u00f6m K, Uhlen M. The Human Protein Atlas\u2014a tool for pathology. J Pathol. 2008;216(4):387\u201393. https:\/\/doi.org\/10.1002\/path.2440.","journal-title":"J Pathol"},{"issue":"3","key":"4984_CR32","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2217\/epi-2017-0118","volume":"10","author":"M Vijayachitra","year":"2018","unstructured":"Vijayachitra M, et al. MethSurv: a web tool to perform multivariable survival analysis using DNA methylation data. Epigenomics. 2018;10(3):277\u201388. https:\/\/doi.org\/10.2217\/epi-2017-0118.","journal-title":"Epigenomics"},{"key":"4984_CR33","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3389\/fonc.2019.00332","volume":"9","author":"Y Bai","year":"2019","unstructured":"Bai Y, et al. YTHDF1 regulates tumorigenicity and cancer stem cell-like activity in human colorectal carcinoma. Front Oncol. 2019;9:332. https:\/\/doi.org\/10.3389\/fonc.2019.00332.","journal-title":"Front Oncol"},{"issue":"1","key":"4984_CR34","doi-asserted-by":"publisher","first-page":"4892","DOI":"10.1038\/s41467-019-12801-6","volume":"10","author":"Y Shi","year":"2019","unstructured":"Shi Y, et al. YTHDF1 links hypoxia adaptation and non-small cell lung cancer progression. Nat Commun. 2019;10(1):4892. https:\/\/doi.org\/10.1038\/s41467-019-12801-6.","journal-title":"Nat Commun"},{"issue":"7743","key":"4984_CR35","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-019-0916-x","volume":"566","author":"D Han","year":"2019","unstructured":"Han D, et al. Anti-tumour immunity controlled through mRNA m(6)A methylation and YTHDF1 in dendritic cells. Nature. 2019;566(7743):270\u20134. https:\/\/doi.org\/10.1038\/s41586-019-0916-x.","journal-title":"Nature"},{"issue":"1","key":"4984_CR36","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12943-020-01161-1","volume":"19","author":"D Jin","year":"2020","unstructured":"Jin D, et al. m(6)A demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107\/LATS2-mediated YAP activity in NSCLC. Mol Cancer. 2020;19(1):40. https:\/\/doi.org\/10.1186\/s12943-020-01161-1.","journal-title":"Mol Cancer"},{"issue":"5","key":"4984_CR37","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1093\/carcin\/bgz152","volume":"41","author":"H Sheng","year":"2020","unstructured":"Sheng H, et al. YTH domain family 2 promotes lung cancer cell growth by facilitating 6-phosphogluconate dehydrogenase mRNA translation. Carcinogenesis. 2020;41(5):541\u201350. https:\/\/doi.org\/10.1093\/carcin\/bgz152.","journal-title":"Carcinogenesis"},{"issue":"6","key":"4984_CR38","doi-asserted-by":"publisher","first-page":"8899","DOI":"10.1002\/jcp.27551","volume":"234","author":"D Zhu","year":"2019","unstructured":"Zhu D, et al. ZC3H13 suppresses colorectal cancer proliferation and invasion via inactivating Ras-ERK signaling. J Cell Physiol. 2019;234(6):8899\u2013907. https:\/\/doi.org\/10.1002\/jcp.27551.","journal-title":"J Cell Physiol"},{"key":"4984_CR39","doi-asserted-by":"publisher","first-page":"578963","DOI":"10.3389\/fonc.2020.578963","volume":"10","author":"PJ Gong","year":"2020","unstructured":"Gong PJ, et al. Analysis of N6-methyladenosine methyltransferase reveals METTL14 and ZC3H13 as tumor suppressor genes in breast cancer. Front Oncol. 2020;10:578963. https:\/\/doi.org\/10.3389\/fonc.2020.578963.","journal-title":"Front Oncol"},{"issue":"6","key":"4984_CR40","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1111\/1759-7714.13097","volume":"10","author":"L Hui","year":"2019","unstructured":"Hui L, et al. CBLL1 is highly expressed in non-small cell lung cancer and promotes cell proliferation and invasion. Thorac Cancer. 2019;10(6):1479\u201388. https:\/\/doi.org\/10.1111\/1759-7714.13097.","journal-title":"Thorac Cancer"},{"issue":"19","key":"4984_CR41","doi-asserted-by":"publisher","first-page":"8391","DOI":"10.26355\/eurrev_201910_19150","volume":"23","author":"HB Qiu","year":"2019","unstructured":"Qiu HB, et al. Downregulation of long non-coding RNA XIST inhibits cell proliferation, migration, invasion and EMT by regulating miR-212-3p\/CBLL1 axis in non-small cell lung cancer cells. Eur Rev Med Pharmacol Sci. 2019;23(19):8391\u2013402. https:\/\/doi.org\/10.26355\/eurrev_201910_19150.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"2","key":"4984_CR42","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1093\/nar\/gky1138","volume":"47","author":"M Pabis","year":"2019","unstructured":"Pabis M, et al. HuR biological function involves RRM3-mediated dimerization and RNA binding by all three RRMs. Nucleic Acids Res. 2019;47(2):1011\u201329. https:\/\/doi.org\/10.1093\/nar\/gky1138.","journal-title":"Nucleic Acids Res"},{"issue":"Pt 3","key":"4984_CR43","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.mce.2015.04.017","volume":"418","author":"ZY Wang","year":"2015","unstructured":"Wang ZY, Yin L. Estrogen receptor alpha-36 (ER-\u03b136): A new player in human breast cancer. Mol Cell Endocrinol. 2015;418(Pt 3):193\u2013206. https:\/\/doi.org\/10.1016\/j.mce.2015.04.017.","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"4984_CR44","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.bbrc.2007.02.145","volume":"356","author":"R Dong","year":"2007","unstructured":"Dong R, et al. Stabilization of Snail by HuR in the process of hydrogen peroxide induced cell migration. Biochem Biophys Res Commun. 2007;356(1):318\u201321. https:\/\/doi.org\/10.1016\/j.bbrc.2007.02.145.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"4984_CR45","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1074\/jbc.M115.693853","volume":"291","author":"Y Zhou","year":"2016","unstructured":"Zhou Y, et al. Loss of scribble promotes snail translation through translocation of HuR and enhances cancer drug resistance. J Biol Chem. 2016;291(1):291\u2013302. https:\/\/doi.org\/10.1074\/jbc.M115.693853.","journal-title":"J Biol Chem"},{"issue":"1","key":"4984_CR46","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s13167-017-0083-9","volume":"8","author":"T Cheng","year":"2017","unstructured":"Cheng T, Zhan X. Pattern recognition for predictive, preventive, and personalized medicine in cancer. EPMA J. 2017;8(1):51\u201360. https:\/\/doi.org\/10.1007\/s13167-017-0083-9.","journal-title":"EPMA J"},{"issue":"5732","key":"4984_CR47","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1126\/science.1110267","volume":"309","author":"M Brandes","year":"2005","unstructured":"Brandes M, Willimann K, Moser B. Professional antigen-presentation function by human gammadelta T Cells. Science (New York, NY). 2005;309(5732):264\u20138. https:\/\/doi.org\/10.1126\/science.1110267.","journal-title":"Science (New York, NY)"},{"issue":"9","key":"4984_CR48","doi-asserted-by":"publisher","first-page":"6044","DOI":"10.4049\/jimmunol.180.9.6044","volume":"180","author":"Z Liu","year":"2008","unstructured":"Liu Z, et al. Protective immunosurveillance and therapeutic antitumor activity of gammadelta T cells demonstrated in a mouse model of prostate cancer. J Immunol (Baltimore, Md: 1950). 2008;180(9):6044\u201353. https:\/\/doi.org\/10.4049\/jimmunol.180.9.6044.","journal-title":"J Immunol (Baltimore, Md: 1950)"},{"issue":"7791","key":"4984_CR49","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink BA, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577(7791):549\u201355. https:\/\/doi.org\/10.1038\/s41586-019-1922-8.","journal-title":"Nature"},{"key":"4984_CR50","doi-asserted-by":"publisher","first-page":"664109","DOI":"10.3389\/fimmu.2021.664109","volume":"12","author":"M Bocchino","year":"2021","unstructured":"Bocchino M, et al. Dendritic cells are the intriguing players in the puzzle of idiopathic pulmonary fibrosis pathogenesis. Front Immunol. 2021;12:664109. https:\/\/doi.org\/10.3389\/fimmu.2021.664109.","journal-title":"Front Immunol"},{"issue":"6","key":"4984_CR51","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1200\/JCO.1999.17.6.1786","volume":"17","author":"M Monz\u00f3","year":"1999","unstructured":"Monz\u00f3 M, et al. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol. 1999;17(6):1786\u201393. https:\/\/doi.org\/10.1200\/JCO.1999.17.6.1786.","journal-title":"J Clin Oncol"},{"issue":"8","key":"4984_CR52","first-page":"1851","volume":"56","author":"MV Blagosklonny","year":"1996","unstructured":"Blagosklonny MV, et al. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Can Res. 1996;56(8):1851\u20134.","journal-title":"Can Res"},{"issue":"11","key":"4984_CR53","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1593\/neo.05355","volume":"7","author":"Y Shi","year":"2005","unstructured":"Shi Y, et al. Optimal classes of chemotherapeutic agents sensitized by specific small-molecule inhibitors of akt in vitro and in vivo. Neoplasia (New York, NY). 2005;7(11):992\u20131000. https:\/\/doi.org\/10.1593\/neo.05355.","journal-title":"Neoplasia (New York, NY)"},{"issue":"1","key":"4984_CR54","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1159\/000493980","volume":"108","author":"E Baudin","year":"2019","unstructured":"Baudin E, et al. Unmet medical needs in pulmonary neuroendocrine (carcinoid) neoplasms. Neuroendocrinology. 2019;108(1):7\u201317. https:\/\/doi.org\/10.1159\/000493980.","journal-title":"Neuroendocrinology"},{"issue":"5","key":"4984_CR55","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.chest.2016.06.018","volume":"151","author":"EM Wolin","year":"2017","unstructured":"Wolin EM. Advances in the diagnosis and management of well-differentiated and intermediate-differentiated neuroendocrine tumors of the lung. Chest. 2017;151(5):1141\u20136. https:\/\/doi.org\/10.1016\/j.chest.2016.06.018.","journal-title":"Chest"},{"issue":"14","key":"4984_CR56","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.7150\/ijbs.45886","volume":"16","author":"N Ding","year":"2020","unstructured":"Ding N, et al. Chidamide increases the sensitivity of non-small cell lung cancer to crizotinib by decreasing c-MET mRNA methylation. Int J Biol Sci. 2020;16(14):2595\u2013611. https:\/\/doi.org\/10.7150\/ijbs.45886.","journal-title":"Int J Biol Sci"},{"issue":"2","key":"4984_CR57","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41397-019-0110-4","volume":"20","author":"Q Meng","year":"2020","unstructured":"Meng Q, et al. Dissecting the m(6)A methylation affection on afatinib resistance in non-small cell lung cancer. Pharmacogenomics J. 2020;20(2):227\u201334. https:\/\/doi.org\/10.1038\/s41397-019-0110-4.","journal-title":"Pharmacogenomics J"},{"issue":"1","key":"4984_CR58","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12885-018-4108-0","volume":"18","author":"C Demuth","year":"2018","unstructured":"Demuth C, et al. The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment. BMC Cancer. 2018;18(1):191. https:\/\/doi.org\/10.1186\/s12885-018-4108-0.","journal-title":"BMC Cancer"},{"issue":"6","key":"4984_CR59","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1073\/pnas.0709662105","volume":"105","author":"CH Yun","year":"2008","unstructured":"Yun CH, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA. 2008;105(6):2070\u20135. https:\/\/doi.org\/10.1073\/pnas.0709662105.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"4984_CR60","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1159\/000443368","volume":"61","author":"O Tetsu","year":"2016","unstructured":"Tetsu O, et al. Drug resistance to EGFR inhibitors in lung cancer. Chemotherapy. 2016;61(5):223\u201335. https:\/\/doi.org\/10.1159\/000443368.","journal-title":"Chemotherapy"},{"issue":"4","key":"4984_CR61","doi-asserted-by":"publisher","first-page":"e307","DOI":"10.1038\/oncsis.2017.17","volume":"6","author":"KR Jakobsen","year":"2017","unstructured":"Jakobsen KR, et al. MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR-mutated, NSCLC HCC827 cells. Oncogenesis. 2017;6(4):e307. https:\/\/doi.org\/10.1038\/oncsis.2017.17.","journal-title":"Oncogenesis"},{"key":"4984_CR62","doi-asserted-by":"publisher","first-page":"101907","DOI":"10.1016\/j.ctrv.2019.101907","volume":"81","author":"T Lian","year":"2019","unstructured":"Lian T, Li C, Wang H. Trametinib in the treatment of multiple malignancies harboring MEK1 mutations. Cancer Treat Rev. 2019;81:101907. https:\/\/doi.org\/10.1016\/j.ctrv.2019.101907.","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"4984_CR63","first-page":"1244","volume":"20","author":"X Wang","year":"2016","unstructured":"Wang X, et al. N1-guanyl-1,7-diaminoheptane enhances the chemosensitivity of NSCLC cells to cetuximab through inhibition of eukaryotic translation initiation factor 5A2 activation. Eur Rev Med Pharmacol Sci. 2016;20(7):1244\u201350.","journal-title":"Eur Rev Med Pharmacol Sci"}],"container-title":["BMC Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-022-04984-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12859-022-04984-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-022-04984-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T15:02:59Z","timestamp":1666191779000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbioinformatics.biomedcentral.com\/articles\/10.1186\/s12859-022-04984-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,19]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["4984"],"URL":"https:\/\/doi.org\/10.1186\/s12859-022-04984-5","relation":{},"ISSN":["1471-2105"],"issn-type":[{"value":"1471-2105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,19]]},"assertion":[{"value":"6 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was waived since we used only publicly available data in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable (public data).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"437"}}